Research collaboration; use of 3-Dimensional¿s DirectedDiversity tech- nology (computer-aided iterative process for gen- erating chemical com- pounds) to discover and refine compounds for a specific agrochemical target
ND
DuPont licensed technology and gets exclusive licenses on all active com- pounds identified; 3-Dimensional gets licensing fees, milestones and royalties (11/98)
Acacia Biosciences Inc.*
American Cyanamid Co. (subsidiary of American Home Products Corp.; NYSE:AHP)
Research collaboration; use of functional genomics and bioinformatics to aid in selection and optimization of lead compounds for crop protection products
ND
Acacia will provide chemical and biological profiles on a class of American Cyanamid¿s compounds for undisclosed fee (1/98)
Acacia Biosciences Inc.*
DuPont Agricultural Enterprise (unit of E.I. duPont de Nemours and Co.; NYSE:DD)
Research collaboration; use of functional genomics and bioinformatics to aid in selection and optimization of lead compounds for crop protection products
ND
Acacia will provide chemical and biological profiles on a class of DuPont¿s compounds for undisclosed fee (6/98)
Acacia Biosciences Inc.*
Novartis Crop Protection (unit of Novartis AG; Switzerland)
Research collaboration; use of functional genomics and bioinformatics to aid in selection and optimization of lead compounds for crop protection products
ND
Acacia will provide chemical and biological profiles on a class of Novartis¿ compounds for undisclosed fee (8/98)
Alanex Corp. (wholly owned subsidiary of Agouron Pharmaceuticals Inc.)
Zeneca Agrochemicals (division of Zeneca Ltd., NYSE:ZEN; U.K.)
Research collaboration; use of Alanex¿s exploratory chemical libraries for screening in Zeneca¿s high-throughput assays for agrochemicals
ND
3-year agreement; Alanex will provide compounds on nonexclusive basis but Zeneca has right to exclusively license any leads for use in agriculture, horticulture, forestry and public health; Alanex retains rights to human pharmaceutical and animal health uses; Alanex gets up-front license fee, annual research support, milestones and royalties (6/98)
BioDiscovery Ltd. (ASX:BID; Australia)
Rhone-Poulenc Agro (unit of RhonePoulenc SA; NYSE: RP; France)
Agreement to screen extracts of Australian insects as source of leads for agrochemical and pharmaceutical products, especially for crop protection products
$1.5M
Agreement is based on findings from BioDiscovery¿s joint venture with CSIRO Entomology; Rhone-Poulenc gets access to extracts from insect library for 3 years; BioDiscovery gets up-front payment of US$0.3M, plus the same payment on 1st and 2nd anniversary (for US$0.6M); it also gets additional payments and milestones of US$0.6M as well as royalties (prices converted at a rate of A$1.66/US$1) (11/98)
Biora AB (Sweden)
St. Jon Laboratories (subsidiary of AgriNutrition Group Ltd.; NASDAQ:AGNU)
Distribution and marketing agreement on Biora¿s Emdovet for treating periodontal disease in animal health market (same product sold for human applications as Emdogain [composed of enamel matrix proteins to initiate regrowth of tooth-supporting tissue])
ND
St. Jons gets exclusive distribution and marketing rights in North America and U.K.(12/98)
BioSource Technologies Inc.*
Dow AgroSciences LLC (wholly owned subsidiary of the Dow Chemical Co.; NYSE:DOW)
Research collaboration; use of BioSource¿s functional genomics technology in Dow¿s high-through-put screens to create specific crop traits
ND
Dow gets rights to all discovered genes that provide useful crop traits; BioSource retains rights to all pharmaceutical and animal health applications; 3-year agreement; other terms ND (9/98)
CombiChem Inc.
Novartis Crop Protection (unit of Novartis AG; Switzerland)
Research collaboration; use of CombiChem¿s computational drug discovery program to generate compounds for use as herbicides, fungicides and insecticides
ND
CombiChem will generate compounds for in vivo testing in whole organisms; CombiChem gets initial fee, research support and milestones; Novartis gets exclusive worldwide rights to develop and market or sublicense products; CombiChem gets royalties (5/98)
CuraGen Corp.
DuPont Agricultural Enterprise (unit of E.I. duPont de Nemours and Co.; NYSE:DD)
Research collaboration; use of genomics technologies to characterize genetic components and metabolic pathways underlying a DuPont crop protection product
ND
ND (7/98)
CuraGen Corp.
Pioneer Hi-Bred International Inc. (NYSE:PHB)
Expansion of 6/97 gene discovery collaboration; use of genomics technologies to discover genes responsible for agricultural seed product performance
ND
Pioneer will double its annual funding from $2.5M/year to $5M/year (4/98)
Demegen Inc. OTC Bulletin Board:DBOT)
Dow AgroSciences LLC (wholly owned subsidiary of the Dow Chemical Co.; NYSE:DOW)
Expansion of 11/97 license agreement on technologies for developing disease-resistant crops to include technologies for increasing nutritional quality and protein content in food and feed crops
ND
Original license agreement, involving Demegen¿s transgenic crop technology, was signed between Demegen and Mycogen Corp. (which was acquired by Dow in 11/98); further details ND (12/98)
Ecogen Inc.
Monsanto Co. (NYSE:MTC)
Revision of 1/96 contract research agreement on enhanced Bt genes
ND
Ecogen will assist Monsanto in expanding its capabilities in the Bt area; amended agreement terminates 1/99 (1 year earlier than original) but Ecogen still gets $10M total per original terms; Monsanto holds 12% of Ecogen stock (2/98)
Enzo Biochem Inc.
Japan Tobacco Inc. (Japan)
License agreement; use of Enzo¿s genetic antisense technology to develop improved strains of rice
ND
Japan Tobacco gets license to use technology in Japan; Enzo gets up-front fee, commercialization payments and royalties (1/98)
EnzyMed Inc.*
Novartis Crop Protection (unit of Novartis AG; Switzerland)
Research collaboration; use of EnzyMed¿s combinatorial biocatalysis technology to create compound libraries (potential crop protection agents)
ND
3-year agreement; EnzyMed gets 1st option to perform lead optimization services on all active hits resulting from Novartis¿ screening of libraries (6/98)
Exelixis Pharmaceuticals Inc.*
Bayer AG (Germany)
Research collaboration; use of Exelixis¿ model system genetics, genomics and bioinformatics to identify screening targets for crop protection agents
$30M
Exelixis will identify and validate targets and develop assays for high-throughput screening against Bayer¿s chemical compound libraries; Bayer will evaluate, develop and commercialize products; Exelixis will also develop expressed sequence tag database for pest species of Bayer¿s choosing; Exelixis gets $30M total in license fees, research support and milestones, as well as royalties; 5-year collaboration (5/98)
Flamel Technologies SA (France)
Monsanto Co. (NYSE:MTC)
Research collaboration; use of Flamel¿s Agsome agrochemical delivery system (nanoencapsulation) to develop enhanced formulation of Roundup herbicide
ND
This agreement expands scope of the parties¿ 8/96 collaboration; Flamel gets R&D funds, milestones and royalties; Monsanto retains right to use Agsome technology in other crop protection products; Flamel retains rights in all areas outside of agrochemicals (1/98)
Forage Genetics* (wholly owned subsidiary of Research Seeds Inc.)
Monsanto Co. (NYSE:MTC)
Research collaboration; incorporation of genes with improved agronomic traits into alfalfa germplasm; initial focus is Roundup Ready alfalfa
ND
Letter of intent signed; Monsanto will contribute gene technology; Forage will provide alfalfa germplasm and transformation technology; companies will broadly license all product improvements to alfalfa breeding and marketing organizations (6/98)
Forage Genetics* (wholly owned subsidiary of Research Seeds Inc.)
Novartis Seed (unit of Novartis AG; Switzerland)
Research collaboration; development, evaluation and release of new NK brand alfalfa varieties with Roundup Ready trait
ND
ND (8/98)
Gene Logic Inc.
Hoechst Schering AgrEvo GmbH (joint venture between Hoechst AG and Schering AG; Germany)
Research collaboration; use of functional genomics to discover genes for crop protection and improvement
$45M
3-year exclusive agreement with possible extension for another 5 years; Gene Logic will identify genes and develop databases for various crops; AgrEvo gets access to Gene Logic¿s flow-thru chip technology for further analysis of identified genes; Gene Logic gets database fees and research funds of $45M over full term; it also gets milestones and royalties (7/98)
GeneMedicine Inc.
Heska Corp. (NASDAQ:HSKA)
Research collaboration; use of GeneMedicine¿s cationic lipid-and polymer-based DNA formulations and delivery technologies (targeted delivery of plasmid-based medicines) for certain immunotherapeutic applications in companion animal health
ND
Heska gets exclusive right to evaluate technologies; GeneMedicine gets option fee; if Heska exercises option on exclusive license, GeneMedicine gets license fee, milestones and royalties (11/98)
GeneTrace Systems Inc.*
Monsanto Co. (NYSE:MTC)
Research collaboration; use of GeneTrace¿s technology in plant and animal genomics; includes use of genotyping methods to improve seed germplasm in crops (corn, soybeans)
$17.2M (equity; % ND)
Monsanto gets series of options to exclusively license all aspects of GeneTrace¿s genomics technologies for plant and animal uses; as part of initial agreement, Monsanto licensed genotyping methods; GeneTrace gets $17.2M total, including R&D funds, equipment purchases, supply agreements and equity investment (4/98)
Incyte Pharmaceuticals Inc.
Zeneca Group plc (NYSE:ZEN; U.K.)
Major collaboration in agrigenomics; extension of 6/96 database agreement (for therapeutics) to include Incyte¿s PhytoSeq database and its microarray technology for use in analyzing gene pathways and monitoring gene expression in plants
ND
Technology allows Zeneca to study multigenic pathways in single experiment; Incyte will apply its high-through-put gene sequencing and bioinformatics technologies to generate gene sequence and expression information on crop plants designated by Zeneca to be included in PhytoSeq database; Zeneca gets access to data from custom and prefabricated micro-arrays; multiyear agreement (12/98)
Lynx Therapeutics Inc.
DuPont Agricultural Enterprise (unit of E.I. duPont de Nemours and Co.; NYSE:DD)
Crop genomics research collaboration; use of Lynx¿s genomics technologies (especially its bead-based system for parallel analyses of large cDNA libraries and genomic DNA molecules or fragments) to study corn, soybeans, wheat and rice; goal is to develop new crop varieties and crop protection products
$60M
DuPont gets exclusive access to Lynx¿s technologies; Lynx gets $60M over 5 years for certain analyses, milestones and delivery of genomic map of certain crop; Lynx gets initial payment of $10M and at least $12M over next 3 years (11/98)
Microbix Biosystems Inc. (TSE:MBX; Canada)
Schering-Plough Animal Health (unit of Schering-Plough Corp.; NYSE:SGP)
Termination of collaboration on adenovirus vector-based recombinant vaccine for rabies in companion animals
ND
Schering-Plough acquired collaboration when it bought Mirobix¿s original partner, Mallinckrodt Veterinary Inc., in 6/97; program does not fit into Schering-Plough¿s core business; Microbix reacquired all product rights and will be paid for 2 outstanding milestones (7/98)
Mycogen Corp.
Rhone-Poulenc Agro (unit of Rhone-Poulenc SA; NYSE:RP; France)
Worldwide plant biotech alliance; pooling of assets to develop and market genetically modified plants and seeds containing multiple traits (especially for insect-resistance and herbicide tolerance); initial focus on cotton and sugar cane
ND
In future, companies plan to incorporate additional agronomic/quality traits (oil or protein content); companies will license products to seed companies; Mycogen will also market directly in North and South America and Europe (7/98)
Neurogen Corp.
Animal Health division of Pfizer Inc. (NYSE:PFE)
License agreement; use of Neurogen¿s small-molecule compounds that work via gamma amino butyric acid neurotransmitter system to develop drugs for treating anxiety and cognitive dysfunction in companion animals
ND
This is expansion of agreement between the companies covering human anxiety disorders and dementia; Neurogen will identify drug candidates; Pfizer will develop them and pay all costs; Neurogen gets milestones and royalties (9/98)
Oxford Asymmetry International plc (LSE:OAI; U.K.)
Dow AgroSciences LLC (wholly owned subsidiary of the Dow Chemical Co.; NYSE:DOW)
Research collaboration; discovery, synthesis and screening of new chemical compounds for agricultural applications
$1.2M
18-month agreement; Oxford Asymmetry gets $1.2M in fees, plus milestones and royalties for each compound developed (3/98)
Oxford GlycoSciences plc (U.K.)
Pioneer Hi-Bred International Inc. (NYSE:PHB)
Research collaboration; use of Oxford GlycoSciences¿ proteomics technology with Pioneer¿s plant gene database to discover genes for improving agricultural seed products; initial focus on corn
$27.5M
5-year collaboration; Oxford will construct protein expression databases for Pioneer; Oxford gets $12.5M up-front plus $15M in R&D funds; it also gets milestones and royalties (9/98)
Paradigm Genetics Inc.*
Bayer AG (Germany)
Collaboration on screening targets for herbicides; Paradigm will analyze function of every gene in rice and Arabidopsis and determine which will make good targets
$40M
Paradigm gets $40M, including milestones, as well as success fees for all products that reach market; Bayer will use assays developed by Paradigm to screen against its chemical compound libraries; Bayer will also evaluate leads in vivo, develop and commercialize products (10/98)
Peptech Ltd. (ASX: PTD; Australia)
Pfizer Inc. (NYSE:PFE)
Agreement to develop methods for large-scale manufacture of Peptech¿s 3rd-generation, long-acting implant for reversible castration of companion animals (contains deslorelin, synthetic variant of gonado-tropin-releasing hormone)
ND
Pfizer will fund initial 12-month program of clinical research as well as development of manufacturing methods and research program at Peptech; Pfizer gets exclusive access to implant technology, for which Peptech gets up-front fee; if milestones reached, project will be continued in expanded form (12/98)
Performance Plants Inc.* (Canada)
Dow AgroSciences LLC (wholly owned subsidiary of the Dow Chemical Co.; NYSE:DOW)
Research collaboration; introduction of growth-enhancement technology and augmented microbial and plant expression technology (GET and AMPLE genes) to improve value and performance of canola and other crops
$1.2M
ND (9/98)
Pharmacopeia Inc.
Novartis Crop Protection (unit of Novartis AG; Switzerland)
Collaboration in agrochemicals; use of Pharmacopeia¿s ECLiPS technology (combinatorial chemistry) to provide small-molecule compounds for screening as crop protection products
ND
Pharmacopeia will provide compounds, which Novartis will screen for product leads; Pharmacopeia gets payments for each library provided, milestones and royalties (12/98)
Phytopharm plc (U.K.)
Heska Corp. (NASDAQ:HSKA)
Evaluation and license option agreement on Phytopharm¿s botanical compounds (whole or partially purified extracts of medicinal plants) for use in companion animal health products
ND
Heska gets exclusive right to evaluate one of Phytopharm¿s compounds and option to develop and market it in North America; if Heska exercises option, Phytopharm gets licensing fee, milestones and royalties; Phytopharm retains manufacturing rights; Heska will also evaluate future compounds for use in animal health (11/98)
United Biomedical Inc.*
Merial Ltd. (U.K.; a Merck & Co. Inc./ Rhone-Poulenc SA company)
License agreement on United Biomedical¿s synthetic peptide-based luteinizing hormone releasing hormone vaccine for prevention of boar taint
ND
ND (12/98)
Vaxcel Inc. (OTC Bulletin Board:VXCL)
Heska Corp. (NASDAQ:HSKA)
License agreement; use of Vaxcel¿s microencapsulation technologies in oral vaccines for companion animals
ND
Vaxcel gets up-front license fee, milestones and royalties (8/98)
Virus Research Institute Inc. (merged with T Cell Sciences Inc. in 8/98 to form Avant Immunotherapeutics Inc.)
Heska Corp. (NASDAQ:HSKA)
Research collaboration and license agreement; use of Virus Research¿s Adjumer vaccine delivery system in vaccines for companion animals
ND
Virus Research will supply Adjumer for formulation with Heska¿s antigens; Virus Research gets license fee, milestones and royalties (2/98)
See subscription options